The overexpression of human epidermal growth factor receptor 2 (HER2), an oncogenic receptor tyrosine kinase, is a common genetic alteration found in approximately 20% of breast cancer patients and is linked to a poor prognosis [94]. This evidence concerns the gene ERBB2 and breast carcinoma.